Selected article for: "adverse outcome and increase risk"
Author: Calvisi, Stefania L.; Ramirez, Giuseppe A.; Scavini, Marina; Da Prat, Valentina; Di Lucca, Giuseppe; Laurenzi, Andrea; Gallina, Gabriele; Cavallo, Ludovica; Borio, Giorgia; Farolfi, Federica; Pascali, Maria; Castellani, Jacopo; Lampasona, Vito; D'Angelo, Armando; Landoni, Giovanni; Ciceri, Fabio; Querini, Patrizia Rovere; Tresoldi, Moreno; Piemonti, Lorenzo
Title: Thromboembolism risk among patients with diabetes/stress hyperglycemia and COVID-19()
  • Cord-id: 5r1dkwxs
  • Document date: 2021_8_5
    • ID: 5r1dkwxs
    Snippet: PURPOSE: Individuals with diabetes/stress hyperglycemia carry an increased risk for adverse clinical outcome in case of SARS-CoV-2 infection. The purpose of this study was to evaluate whether this risk is, at least in part, modulated by an increase of thromboembolic complications. METHODS: We prospectively followed 180 hospitalized patients with confirmed COVID-19 pneumonia admitted to the Internal Medicine Units of San Raffaele Hospital. Data from 11 out of 180 patients were considered incomple
    Document: PURPOSE: Individuals with diabetes/stress hyperglycemia carry an increased risk for adverse clinical outcome in case of SARS-CoV-2 infection. The purpose of this study was to evaluate whether this risk is, at least in part, modulated by an increase of thromboembolic complications. METHODS: We prospectively followed 180 hospitalized patients with confirmed COVID-19 pneumonia admitted to the Internal Medicine Units of San Raffaele Hospital. Data from 11 out of 180 patients were considered incomplete and excluded from the analysis. We analysed inflammation, tissue damage biomarkers, hemostatic parameters, thrombotic events (TEs) and clinical outcome according to the presence of diabetes/stress hyperglycemia. RESULTS: Among 169 patients, 51 (30.2%) had diabetes/stress hyperglycemia. Diabetes/stress hyperglycemia and fasting blood glucose (FBG) were associated with increased inflammation and tissue damage circulating markers, higher D-dimer levels, increased prothrombin time and lower antithrombin III activity. Forty-eight venous and 10 arterial TEs were identified in 49 (29%) patients. Diabetes/stress hyperglycemia (HR 2.71, p = 0.001), fasting blood glucose (HR 4.32, p < 0.001) and glucose variability (HR 1.6, p < 0.009) were all associated with an increased risk of thromboembolic complication. TEs significantly increased the risk for an adverse clinical outcome only in the presence of diabetes/stress hyperglycemia (HR 3.05, p = 0.010) or fasting blood glucose ≥7 mmol/L (HR 3.07, p = 0.015). CONCLUSIONS: Thromboembolism risk is higher among patients with diabetes/stress hyperglycemia and COVID-19 pneumonia and is associated to poor clinical outcome. In case of SARS-Cov-2 infection patients with diabetes/stress hyperglycemia could be considered for a more intensive prophylactic anticoagulation regimen.

    Search related documents:
    Co phrase search for related documents
    • active bleeding and admission prior: 1
    • active bleeding and lmwh low molecular weight heparin: 1, 2
    • active bleeding and low molecular weight: 1, 2, 3
    • active bleeding and low molecular weight heparin: 1, 2, 3
    • acute syndrome and additional investigation: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12
    • acute syndrome and admission prior: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • acute syndrome and lmwh low molecular weight heparin: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19
    • acute syndrome and logistic regression: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • acute syndrome and logistic regression assess: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14
    • acute syndrome and low antithrombin iii: 1, 2
    • acute syndrome and low antithrombin iii activity: 1
    • acute syndrome and low molecular weight: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • acute syndrome and low molecular weight heparin: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • acute syndrome and luciferase immunoprecipitation system: 1
    • additional investigation and logistic regression: 1, 2
    • admission prior and lmwh low molecular weight heparin: 1, 2
    • admission prior and logistic regression: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • admission prior and low molecular weight: 1, 2
    • admission prior and low molecular weight heparin: 1, 2